ERBB2 and neoplasm: The analysed biological factors were selected on the basis of their high utility score in the tumour marker grading system (Isaacs et al, 2001), with evidence coming either from prospective trials or meta-analysis (ER, PR, HER2, UPA and PAI-1), or at least from large retrospective studies (TK).